Treatment of central giant cell granuloma in children with denosumab. Issue 3 (21st October 2020)

• Record Type: Journal Article
• Authors: Choe, Michelle; Smith, Valeria; Okcu, M. Fatih; Wulff, Jade; Gruner, Stephanie; Huisman, Thierry A.G.M.; Venkatramani, Rajkumar
• Is Part Of: Pediatric blood & cancer. Volume 68:Issue 3(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-10-21
• Subjects: central giant cell granuloma -- denosumab -- hypercalcemia -- hypocalcemia -- pediatric; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28778
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Central giant cell granuloma (CGCG) is a benign but locally aggressive intraosseous lesion of the mandible. Historically, it is treated by curettage or resection. Medical therapy is indicated when surgery is associated with increased morbidity or in adjuvant setting to decrease recurrence. Treatment of CGCG with denosumab, a receptor activator of nuclear factor kappa‐beta (RANK) ligand inhibitor, is not well studied, especially in children. Here, we describe our experience with the use of denosumab in the treatment of six children with CGCG. All patients had a favorable response with manageable side effects, which suggests that denosumab is an effective treatment option without increased morbidity.